» Articles » PMID: 30486716

Caspase Cleavage of Gelsolin Is an Inductive Cue for Pathologic Cardiac Hypertrophy

Overview
Date 2018 Nov 30
PMID 30486716
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background Cardiac hypertrophy is an adaptive remodeling event that may improve or diminish contractile performance of the heart. Physiologic and pathologic hypertrophy yield distinct outcomes, yet both are dependent on caspase-directed proteolysis. This suggests that each form of myocardial growth may derive from a specific caspase cleavage event(s). We examined whether caspase 3 cleavage of the actin capping/severing protein gelsolin is essential for the development of pathologic hypertrophy. Methods and Results Caspase targeting of gelsolin was established through protein analysis of hypertrophic cardiomyocytes and mass spectrometry mapping of cleavage sites. Pathologic agonists induced late-stage caspase-mediated cleavage of gelsolin. The requirement of caspase-mediated gelsolin cleavage for hypertrophy induction was evaluated in primary cardiomyocytes by cell size analysis, monitoring of prohypertrophy markers, and measurement of hypertrophy-related transcription activity. The in vivo impact of caspase-mediated cleavage was investigated by echo-guided intramyocardial injection of adenoviral-expressed gelsolin. Expression of the N-terminal gelsolin caspase cleavage fragment was necessary and sufficient to cause pathologic remodeling in isolated cardiomyocytes and the intact heart, whereas expression of a noncleavable form prevents cardiac remodeling. Alterations in myocardium structure and function were determined by echocardiography and end-stage cardiomyocyte cell size analysis. Gelsolin secretion was also monitored for its impact on naïve cells using competitive antibody trapping, demonstrating that hypertrophic agonist stimulation of cardiomyocytes leads to gelsolin secretion, which induces hypertrophy in naïve cells. Conclusions These results suggest that cell autonomous caspase cleavage of gelsolin is essential for pathologic hypertrophy and that cardiomyocyte secretion of gelsolin may accelerate this negative remodeling response.

Citing Articles

MicroRNA205: A Key Regulator of Cardiomyocyte Transition from Proliferative to Hypertrophic Growth in the Neonatal Heart.

Weldrick J, Yi R, Megeney L, Burgon P Int J Mol Sci. 2024; 25(4).

PMID: 38396885 PMC: 10889831. DOI: 10.3390/ijms25042206.


Proteolytic activation of fatty acid synthase signals pan-stress resolution.

Wei H, Weaver Y, Yang C, Zhang Y, Hu G, Karner C Nat Metab. 2024; 6(1):113-126.

PMID: 38167727 PMC: 10822777. DOI: 10.1038/s42255-023-00939-z.


Actin-Binding Proteins in Cardiac Hypertrophy.

Pan C, Wang S, Liu C, Ren Z Cells. 2022; 11(22).

PMID: 36428995 PMC: 9688942. DOI: 10.3390/cells11223566.


Caspase Cleavage of Gelsolin Is an Inductive Cue for Pathologic Cardiac Hypertrophy.

Putinski C, Abdul-Ghani M, Brunette S, Burgon P, Megeney L J Am Heart Assoc. 2018; 7(23):e010404.

PMID: 30486716 PMC: 6405540. DOI: 10.1161/JAHA.118.010404.

References
1.
Abdul-Ghani M, Dufort D, Stiles R, De Repentigny Y, Kothary R, Megeney L . Wnt11 promotes cardiomyocyte development by caspase-mediated suppression of canonical Wnt signals. Mol Cell Biol. 2010; 31(1):163-78. PMC: 3019854. DOI: 10.1128/MCB.01539-09. View

2.
Li G, Shi Y, Chen Y, Sun M, Sader S, Maekawa Y . Gelsolin regulates cardiac remodeling after myocardial infarction through DNase I-mediated apoptosis. Circ Res. 2009; 104(7):896-904. DOI: 10.1161/CIRCRESAHA.108.172882. View

3.
Fujita J, Crane A, Souza M, Dejosez M, Kyba M, Flavell R . Caspase activity mediates the differentiation of embryonic stem cells. Cell Stem Cell. 2008; 2(6):595-601. PMC: 2494585. DOI: 10.1016/j.stem.2008.04.001. View

4.
Bell R, Megeney L . Evolution of caspase-mediated cell death and differentiation: twins separated at birth. Cell Death Differ. 2017; 24(8):1359-1368. PMC: 5520454. DOI: 10.1038/cdd.2017.37. View

5.
Hill J, Olson E . Cardiac plasticity. N Engl J Med. 2008; 358(13):1370-80. DOI: 10.1056/NEJMra072139. View